Page 226 - Genentech News Today

– Data showcase the potential of glofitamab and mosunetuzumab to address diverse patient needs – – Data presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab, given as a fixed course, induced early and durable responses in people with heavily pretreated large B-cell lymphoma – – 27-month follow-up data showed mosunetuzumab continued to induce high and durable responses in people with relapsed or refractory f...

The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in previously untreated or minimally treated infants with severe haemophilia

The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in previously untreated or...

The HAVEN 7 study was designed to further confirm the benefit of preventative treatment with Hemlibra from birth in previously untreated or minimally treated infants with severe haemophilia A without... | December 11, 2022

Investegate announcements from F. Hoffmann-La Roche Ltd, Roche’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition

The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and haemolysis control in people with paroxysmal nocturnal...

The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and haemolysis control in people with paroxysmal nocturnal hemoglobinuria (PNH) 1COMMODORE 3 is the first China-specific

A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

Investegate announcements from F. Hoffmann-La Roche Ltd, Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningful bleed control in infants from birth

– The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in previously untreated or minimally treated infants with severe hemophilia A without inhibitors –– 77.8% of participants had no bleeding episodes that required treatment –– In addition, r...